X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Brazil approves Sinovac and Astrazeneca Covid-19 vaccines for emergency use

Content Team by Content Team
19th January 2021
in News
Brazil approves Sinovac and Astrazeneca Covid-19 vaccines for emergency use

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Brazil has granted approval to AstraZeneca and Chinese firm Sinovac Biotech’c Covid-19 vaccines for emergency use, allowing the country to begin inoculation as cases surge.

Brazilian health regulator Anvisa approved the vaccines citing a rise in cases, as well as the absence of options for Covid-19 treatment, Bloomberg reported. Anvisa director Meiruze Freitas said that even though government technicians said they require more information about the vaccine, its benefits surpass the risks.

The media company quoted Freitas as saying: “We must continue monitoring the vaccines to capture adverse effects that were perhaps not seen in trials.”

Notably, Sao Paulo started inoculating people minutes after Anvisa gave approval. Health Minister Eduardo Pazuello said in a press meet in Rio de Janeiro that the government would not do a ‘photo op’ vaccination.

Pazuello added that after a ‘symbolic delivery’ of vaccines to states on 18 January, the vaccination programme will begin on 20 January with delivery based on locations which are at higher risk, in a bid to provide more doses.

Initially, the elderly, Brazil’s local population and healthcare staff will receive the vaccines. In a separate development, Anvisa sought additional data on Russia’s Covid-19 vaccine, Sputnik V, before considering its approval for emergency use.

The documents backing drugmaker Uniao Quimica’s application for emergency use of the vaccine said that it failed to meet minimum criteria, Reuters reported Brazil’s health regulator as saying.

According to the Health Ministry’s website, the request failed to deliver required assurances on Phase III clinical trials and issues related to the vaccine manufacturing. In November, Sinovac announced plans to resume the Phase III trial of the Inactivated Covid-19 vaccine, CoronaVaC, after Anvisa authorised its resumption.

Previous Post

CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Next Post

Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In